LAWRENCE, Mass.--(BUSINESS WIRE)--Nexcelom Bioscience LLC, provider of innovative devices and instruments for cell-based assays in cancer research and drug discovery, today announced it continues to ...

Nexcelom Bioscience LLC has announced it has extended its product platform with the launch of the Cellometer Auto M10™ automatic cell counter. The Auto M10 maintains the user benefits of the ...

CAMBRIDGE, Mass., Nov. 18, 2019 /PRNewswire/ -- Nexcelom Biosciences announced the donation of five Cellometer Auto 2000 Automated Cell Viability Counters to LabCentral. This will support advances in ...

Ampersand Capital Partners has sold Nexcelom Bioscience to PerkinElmer for $260 million. Based in Lawrence, Massachusetts, Nexcelom is a provider of automated cell counting solutions. WELLESLEY, Mass.

The Cellaca™ MX utilizes Nexcelom's innovative cellular analysis technology for accurate cell sample concentration, viability and morphology measurements. Features of the Cellaca™ MX include: ...

Lawrence, Massachusetts-based Nexcelom Bioscience, a provider of cell counting and analysis products for biomedical research and the biopharma industry, has secured an undisclosed amount of funding.

Expertise in Automated Cell Counting and Analysis In 2003, the founders of Nexcelom introduced the CP2, a convenient tool to assist with manual cell counting. According to Dr. Jean Qiu, founder and ...

(RTTNews) - PerkinElmer, Inc. (PKI) Wednesday said it has acquired Nexcelom Bioscience for $260 million in cash. The transaction is expected to close during the second quarter of 2021. Nexcelom is a ...

WELLESLEY, Mass., June 25, 2021 /PRNewswire/ -- Ampersand Capital Partners announced today that it has completed the sale of Nexcelom Bioscience, one of its portfolio companies and a leading provider ...

Nexcelom Bioscience is a biotechnology company composed of biological scientists, software developers, and mechanical engineers who are dedicated to advancing the field of biomedical research. It is a ...

PerkinElmer Inc. (PKI) has agreed to acquire Nexcelom Bioscience for a total cash consideration of $260 million. The acquisition is expected to close in Q2. PerkinElmer serves the diagnostics, life ...